Irina Staatz-Granzer

FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction.

HERMAL Kurt Herrmann GmbH & Co. oHG provides skin care products. The company develops products for the treatment of skin related diseases. It is a dermatological company with marketing and sales departments throughout Europe and a production unit based in Germany. HERMAL Kurt Herrmann was founded in 1946 and is headquartered in Reinbek, Germany.

U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany.

BioNet Pharma GmbH engages in development of medical devices, pharmaceutical drugs and regenerative medical products. Its pipeline covers pre-clinical and clinical development programs in osteoarthritis, inflammatory joint disease, cartilage injury, and severe gingival inflammation. The company is headquartered in Martinsried, Germany.

BliNK Therapeutics Ltd. is a holding company which produces monoclonal antibodies using a novel platform. The platform technology provides a new way of activating the immune system’s B cells to produce antibodies in response to a specific antigen. The company was founded in 2011 and is headquartered in Marlow, the United Kingdom.